Compositions and Methods for Inhibition of Fat-Specific Protein 27
Description of Invention:
FSP27 expression is regulated by PPARgamma, a gene known to play a critical role in the development of fatty liver. Over-expression of FSP27 results in an increase in triglyceride accumulation and an increase in cystolic vacuoles containing lipid droplets which are associated with development of fatty liver disease or hepatic steatosis. This abnormal retention of lipids in liver cells occurs in diabetes and alcoholism and is correlated with decreased liver function which can often lead to cirrhosis and sometimes death. Presently, there are no adequate therapies for fatty liver disease.
This technology is directed towards compositions and methods of inhibiting FSP27, which include antisense compounds, small molecule inhibitors and antibodies that target FSP27.
Application:
Potential new shRNA based therapy for steatotic liver disease (fatty liver).
Market:
Approximately 20 to 30% of the U.S. population has some degree of fatty liver disease, making it the most prevalent liver disease. Meanwhile, cirrhosis is one of the top ten causes of death in the U.S.
Development Status:
Preclinical studies are in progress.
Relevant Publication: K Matsusue, T Kusakabe, T Noguchi, S Takiguchi, T Suzuki, S Yamano, FJ Gonzalez.: Hepatic steatosis in the leptin-deficient mouse is promoted by the PPARgamma target gene, fat-specific protein 27. Cell Metab. 2008 Apr;7(4):302-311. [PubMed abs]
Licensing Status: Available for licensing
Collaborative Research Opportunity:
The Laboratory of Metabolism, National Cancer Institute, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize inhibitors of FSP27 for treatment of fatty liver disease. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
For Additional Information Please Contact: Fatima Sayyid M.H.P.M.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4521
Email: sayyidf@mail.nih.gov
Fax: (301) 402-0220
